Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.945 USD | -4.71% | -2.70% | +6.15% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.15% | 471M | |
+9.15% | 114B | |
+11.55% | 104B | |
-13.44% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.72% | 17.89B | |
+7.93% | 14.28B | |
+34.84% | 12.55B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Cantor Fitzgerald Adjusts Price Target on Fate Therapeutics to $5 From $8, Maintains Neutral Rating